Source:http://linkedlifedata.com/resource/pubmed/id/11593317
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2001-10-10
|
pubmed:abstractText |
Two cycles of high-dose chemotherapy with stem cell support (HDC) may increase the total dose delivered and dose intensity. A brief induction phase and different non-cross-resistant agents for each HDC cycle were used to avoid drug resistance. Twenty-six women with metastatic BC had induction and stem cell mobilization with two cycles of doxorubicin/G-CSF given every 14 days. Patients with stable disease or better after induction received HD CTCb followed by HD melphalan and dose-escalated paclitaxel. At 475 mg/m(2) of paclitaxel by 24-h infusion, dose-limiting transient peripheral sensory neuropathy was encountered. No toxic deaths occurred. Complete and near complete response after completion of therapy was achieved in 22 (85%) of 26 patients. The median EFS was 38 months. The median OS has not yet been reached. At a median follow-up of 33 (25-43) months, actuarial EFS and OS were 54% (95% confidence interval (CI), 39-69%) and 69% (95% CI, 56-79%), respectively. This double transplant approach lasts only 14 weeks and is feasible, safe, and tolerable. Whilst selection biases may in part contribute to favorable EFS and OS, a randomized comparison of standard therapy vs double transplant in both metastatic and locally advanced breast cancer is warranted.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0268-3369
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
447-54
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11593317-Adult,
pubmed-meshheading:11593317-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11593317-Breast Neoplasms,
pubmed-meshheading:11593317-Combined Modality Therapy,
pubmed-meshheading:11593317-Disease-Free Survival,
pubmed-meshheading:11593317-Doxorubicin,
pubmed-meshheading:11593317-Drug Administration Schedule,
pubmed-meshheading:11593317-Female,
pubmed-meshheading:11593317-Follow-Up Studies,
pubmed-meshheading:11593317-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11593317-Humans,
pubmed-meshheading:11593317-Melphalan,
pubmed-meshheading:11593317-Middle Aged,
pubmed-meshheading:11593317-Neoplasm Metastasis,
pubmed-meshheading:11593317-Neoplasm Recurrence, Local,
pubmed-meshheading:11593317-Paclitaxel,
pubmed-meshheading:11593317-Remission Induction,
pubmed-meshheading:11593317-Survival Rate,
pubmed-meshheading:11593317-Treatment Failure,
pubmed-meshheading:11593317-Treatment Outcome
|
pubmed:year |
2001
|
pubmed:articleTitle |
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|